Deutsch
Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Deutsch
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Atea Pharmaceuticals
(NASDAQ:AVIR)
Intraday
$3.70
-0.03
[-0.80%]
After-Hours
$3.70
0
[0.00%]
Get Report
Watch
Perks
Buy
Compare Brokers
$3.70
-0.03
[-0.80%]
At close: Apr 24
$3.70
0
[0.00%]
After Hours: 4:01PM EDT
Get Report
Watch
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for Atea Pharmaceuticals Stock (NASDAQ:AVIR)
Atea Pharmaceuticals Stock (NASDAQ: AVIR)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Wednesday, March 27, 2024
Atea Pharmaceuticals Completes Patient Enrollment In Global Phase 3 SUNRISE-3 Trial Evaluating Bemnifosbuvir For COVID-19 In High-Risk Patients
Benzinga Newsdesk
-
Mar 27, 2024, 7:05AM
Wednesday, February 28, 2024
Recap: Atea Pharmaceuticals Q4 Earnings
Benzinga Insights
-
Feb 28, 2024, 4:35PM
Atea Pharmaceuticals Q4 2023 GAAP EPS $(0.47) Beats $(0.51) Estimate
Benzinga Newsdesk
-
Feb 28, 2024, 4:31PM
Earnings Scheduled For February 28, 2024
Benzinga Insights
-
Feb 28, 2024, 6:24AM
Tuesday, February 27, 2024
Atea Pharmaceuticals Earnings Preview
Benzinga Insights
-
Feb 27, 2024, 3:01PM
Tuesday, January 09, 2024
Atea Pharmaceuticals' Hepatitis C Virus Candidate Shows Efficacy
Vandana Singh
-
Jan 9, 2024, 1:33PM
Monday, January 08, 2024
Atea Pharmaceuticals Announces Initial Data from Phase 2 Study for Hepatitis C Virus And Significant Enrollment Milestone For Phase 3 SUNRISE-3 Trial For COVID-19
Benzinga Newsdesk
-
Jan 8, 2024, 4:09PM
Monday, December 18, 2023
Atea Pharmaceuticals Inc. Receives Orphan Designation Status From U.S. FDA For A Phosphoramidate Oral Prodrug Of A Unique 6-Modified Purine Nucleotide For Treatment Of Disease Caused By Dengue Virus
Happy Mohamed
-
Dec 18, 2023, 9:49AM
Wednesday, November 08, 2023
Atea Pharmaceuticals Q3 EPS $(0.40) Beats $(0.48) Estimate
Benzinga Newsdesk
-
Nov 8, 2023, 5:19PM
Earnings Scheduled For November 8, 2023
Benzinga Insights
-
Nov 8, 2023, 4:21AM
Tuesday, November 07, 2023
Atea Pharmaceuticals's Earnings Outlook
Benzinga Insights
-
Nov 7, 2023, 1:01PM
Monday, October 02, 2023
Stocks That Hit 52-Week Lows On Monday
Benzinga Insights
-
Oct 2, 2023, 1:00PM
Thursday, August 10, 2023
Benzinga's Top Ratings Upgrades, Downgrades For August 10, 2023
Benzinga Insights
-
Aug 10, 2023, 11:00AM
JP Morgan Downgrades Atea Pharmaceuticals to Underweight
Benzinga Newsdesk
-
Aug 10, 2023, 5:28AM
Tuesday, August 08, 2023
Atea Pharmaceuticals Q2 EPS $(0.34) Beats $(0.47) Estimate
Benzinga Newsdesk
-
Aug 8, 2023, 5:39PM
Earnings Scheduled For August 8, 2023
Benzinga Insights
-
Aug 8, 2023, 4:48AM
Monday, August 07, 2023
Earnings Preview For Atea Pharmaceuticals
Benzinga Insights
-
Aug 7, 2023, 3:01PM
Thursday, June 15, 2023
Atea Pharma Dosed First Patient in Phase 2 Study for Treatment of Hepatitis C with Bemnifosbuvir and Ruzasvir Combination
Benzinga Newsdesk
-
Jun 15, 2023, 7:04AM
Tuesday, May 30, 2023
Why Nvidia Shares Are Trading Higher By Over 5%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Lisa Levin
-
May 30, 2023, 1:27PM
Atea Pharmaceuticals shares are trading lower after the company rejected an unsolicited proposal from Tang Capital Partners on behalf of Concerta Biosciences.
Benzinga Newsdesk
-
May 30, 2023, 12:35PM
Skyline Champion, Atea Pharmaceuticals And Other Big Stocks Moving Lower On Tuesday
Lisa Levin
-
May 30, 2023, 10:58AM
Atea Pharmaceuticals' Board Unanimously Rejects Unsolicited Proposal From Tang Capital Partners' Affiliate, Concentra Biosciences
Benzinga Newsdesk
-
May 30, 2023, 7:11AM
Tuesday, May 23, 2023
Atea Pharmaceuticals Confirms Receipt Of Unsolicited Proposal From Tang Capital Partners' Affiliate, Concentra Biosciences To Acquire All Outstanding Common Shares Of Atea For $5.75/Share In Cash, Plus 80% Payable From Any License Or Disposition
Happy Mohamed
-
May 23, 2023, 4:13PM
Monday, May 22, 2023
Biotech Bargain Hunt: Concentra Biosciences Eyes Atea's Promising COVID-19 Response
Vandana Singh
-
May 22, 2023, 5:37PM
Atea Pharmaceuticals shares are trading higher after Tang Capital Partners affiliate, Concentra, sent an acquisition proposal to the company with terms to acquire all of its outstanding common stock.
Benzinga Newsdesk
-
May 22, 2023, 3:30PM
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga Insights
-
May 22, 2023, 1:31PM
Why ZIM Integrated Shipping Services Shares Are Trading Lower By 14%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Lisa Levin
-
May 22, 2023, 1:20PM
VectivBio Holding, Greenhill, Atea Pharmaceuticals And Other Big Stocks Moving Higher On Monday
Lisa Levin
-
May 22, 2023, 10:31AM
US Stocks Mixed; Nordic American Tankers Posts Upbeat Results
Lisa Levin
-
May 22, 2023, 9:50AM
Tang Capital Partners, Concentra Sent Acquisition Proposal To Atea Pharmaceuticals With Terms To Acquire All Of Its Outstanding Common Stock
Benzinga Newsdesk
-
May 22, 2023, 9:06AM
Tang Capital Partners Reports 3.6% Stake In Atea Pharmaceuticals
Benzinga Newsdesk
-
May 22, 2023, 9:03AM
Monday, May 08, 2023
Atea Pharmaceuticals Q1 EPS $(0.43) Beats $(0.48) Estimate
Benzinga Newsdesk
-
May 8, 2023, 5:29PM
Earnings Scheduled For May 8, 2023
Benzinga Insights
-
May 8, 2023, 9:03AM
Friday, May 05, 2023
Earnings Preview: Atea Pharmaceuticals
Benzinga Insights
-
May 5, 2023, 3:01PM
Tuesday, April 25, 2023
The FDA Has Granted Fast Track Designation To Atea Pharmaceuticals' Bemnifosbuvir For COVID-19
Benzinga Newsdesk
-
Apr 25, 2023, 7:18AM
Wednesday, April 12, 2023
Atea Pharmaceuticals Announced The Presentation Of The Full Results From The MORNINGSKY Phase 3 Trial Of Bemnifosbuvir For Covid-19. Bemnifosbuvir Patients Experienced A 71% Relative Reduction In Risk Of Hospitalization, Regardless Of Vaccination Status
Benzinga Newsdesk
-
Apr 12, 2023, 7:08AM
Friday, March 24, 2023
Stocks That Hit 52-Week Lows On Friday
Benzinga Insights
-
Mar 24, 2023, 12:05PM
Thursday, March 16, 2023
JP Morgan Maintains Neutral on Atea Pharmaceuticals, Lowers Price Target to $8
Benzinga Newsdesk
-
Mar 16, 2023, 8:46AM
Tuesday, March 14, 2023
Atea Pharmaceuticals Announced The Presentation Of New Phase 1, In Vitro And In Vivo Data That Demonstrate Key Profile Attributes Of Atea's Lead Drug Candidate, Bemnifosbuvir, For Covid-19 And Hepatitis C
Benzinga Newsdesk
-
Mar 14, 2023, 7:18AM
Wednesday, March 08, 2023
Atea Pharmaceuticals Announced New Data Showcasing Favorable Profile of Bemnifosbuvir for Treatment of COVID-19 and Hepatitis C to be Presented at 2023 International Conference on Antiviral Research
Charles Gross
-
Mar 8, 2023, 7:16AM
Wednesday, March 01, 2023
Stocks That Hit 52-Week Lows On Wednesday
Benzinga Insights
-
Mar 1, 2023, 1:30PM
Tuesday, February 28, 2023
Atea Pharmaceuticals Q4 EPS $(0.41) Beats $(0.45) Estimate
Benzinga Newsdesk
-
Feb 28, 2023, 4:24PM
Stocks That Hit 52-Week Lows On Tuesday
Benzinga Insights
-
Feb 28, 2023, 12:56PM
Earnings Scheduled For February 28, 2023
Benzinga Insights
-
Feb 28, 2023, 4:34AM
Monday, February 27, 2023
Preview: Atea Pharmaceuticals's Earnings
Benzinga Insights
-
Feb 27, 2023, 12:02PM
Stocks That Hit 52-Week Lows On Monday
Benzinga Insights
-
Feb 27, 2023, 11:44AM
Friday, February 24, 2023
Stocks That Hit 52-Week Lows On Friday
Benzinga Insights
-
Feb 24, 2023, 2:11PM
Wednesday, February 22, 2023
Stocks That Hit 52-Week Lows On Wednesday
Benzinga Insights
-
Feb 22, 2023, 10:45AM
Wednesday, February 15, 2023
Stocks That Hit 52-Week Lows On Wednesday
Benzinga Insights
-
Feb 15, 2023, 10:33AM
Friday, January 27, 2023
SVB Leerink Maintains Market Perform on Atea Pharmaceuticals, Lowers Price Target to $6
Benzinga Newsdesk
-
Jan 27, 2023, 6:46AM
Show more
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch